Skip to Content

Bextra

Active Substance: valdecoxib
Common Name: valdecoxib
ATC Code: M01AH03
Marketing Authorisation Holder: Pharmacia - Pfizer EEIG
Active Substance: valdecoxib
Status: Withdrawn
Authorisation Date: 2003-03-27
Therapeutic Area: Arthritis, Rheumatoid Osteoarthritis Dysmenorrhea
Pharmacotherapeutic Group: Antiinflammatory and antirheumatic products

Therapeutic Indication

Symptomatic relief in the treatment of osteoarthritis or rheumatoid arthritis.
Treatment of primary dysmenorrhoea.

The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient's overall risk (see sections 4.3, 4.4).

The marketing authorisation for Bextra has not been renewed by the marketing authorisation holder and is now withdrawn.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide